Blocking nitrosylation boosts treatment for NRAS melanoma
Researchers at Moffitt Cancer Center have discovered that blocking a chemical process called nitrosylation can make aggressive NRAS-mutant melanoma more responsive to treatment.
List view / Grid view
Researchers at Moffitt Cancer Center have discovered that blocking a chemical process called nitrosylation can make aggressive NRAS-mutant melanoma more responsive to treatment.
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
Researchers at ETH Zurich in Switzerland have mapped the complex network cells use to repair their genetic material, revealing previously hidden vulnerabilities in cancer cells.
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
Discover how Immorta Bio's cellular therapies are addressing cancer and liver failure, with the potential to transform healthcare.
A new cancer therapy combines multiple treatment strategies into a single graphene oxide-based nanocomposite. It uses bacterial components to enhance immune response and scalability, creating a powerful and cost-effective approach to tackling tumours.
Scientists at UT Health San Antonio have identified PSPC1 in mouse models as a promising new drug target for acute myeloid leukaemia (AML), a deadly blood cancer with limited treatment options.
A government-funded research team has identified focal adhesion kinase (FAK) as a key driver of melanoma metastasis to the brain. This discovery could revolutionise treatment by not only addressing the condition but also preventing its spread to the brain.
Scientists in Japan have developed a new radioactive drug that emits alpha particles, showing promise for targeting metastatic melanoma - an aggressive skin cancer resistant to many conventional treatments.
High-grade glioma, an aggressive brain cancer affecting both paediatric and adult patients, remains difficult to treat. A collaborative study from the University of Michigan, Dana-Farber Cancer Institute, and the Medical University of Vienna reveals a promising new treatment approach.
Pancreatic cancer is notoriously hard to treat, especially when it spreads to the liver in advanced stages. Researchers at UCLA’s California NanoSystems Institute (CNSI) have developed an innovative nanoparticle technology to tackle this challenge.
A commonly prescribed diabetes medication could significantly enhance long-term recovery prospects for cancer patients by reducing their risk of heart failure, a new study from the University of East Anglia (UEA) reveals.
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
A new discovery from the University of Geneva highlights the crucial role of the CH25H enzyme, which is found in cancerous lymphatic cells. This enzyme plays a key part in activating immune cells, opening up a promising pathway for improving the success of cancer immunotherapies.